ClinicalTrials.gg
CompletedNCT00457795Updated Nov 24, 2011Results posted

24-hour IOP-lowering Effect of Brimonidine 0.1%

A Phase 4 interventional study of brimonidine 0.1% (Alphagan® P) in Open-angle Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-11-24.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing brimonidine in Glaucoma, Open-Angle — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma, Open-Angle.

Enrollment
17th of 17
15 · median 120
Started
2006
with 1 other
Phase 4
11 of 18
1 open now
Registered
4th of 18
by date
Lead sponsor
6 of 18
Allergan

Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2006, is one of 11 in phase 4, and was the 4th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 18 studies testing brimonidine in Glaucoma, Open-Angle is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing brimonidine in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

03

Conditions studied

  • Open-angle Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with open-angle glaucoma or ocular hypertension

Exclusion criteria

Exclusion Criteria:

  • allergy to brimonidine
  • inability to complete 24 hour stay for monitoring
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    brimonidine 0.1%

    brimonidine 0.1%

    Drug: brimonidine 0.1% (Alphagan® P)

Interventions

06

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

    IOP for a 24-hour period separated into diurnal(7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eye. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.

    Time frame: Week 4

Secondary outcomes

  1. Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

    Change from baseline in IOP for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eey. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period. A negative number change from baseline indicates an improvement.

    Time frame: Baseline, Week 4

  2. Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4

    Ocular perfusion pressure (OPP) calculated for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.

    Time frame: Week 4

  3. Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4

    Change in ocular perfusion pressure (OPP) calculated over a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at Week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.

    Time frame: Week 4

07

Results

Posted Nov 24, 2011

Participant flow

Participant flow — Overall Study
MilestoneBrimonidine 0.1%
Started15
Completed15
Not completed0

Outcome measures

PrimaryIntraocular Pressure (IOP) for a 24-Hour Period at Week 4

IOP for a 24-hour period separated into diurnal(7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eye. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.

Time frame:
Week 4
Reported as:
Mean · Millimeters of mercury (mmHg)
Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
Millimeters of mercury (mmHg)Brimonidine 0.1%
Diurnal IOP Sitting at Week 416.8 ± 2.8
Diurnal IOP Supine at Week 421.1 ± 2.3
Nocturnal IOP Supine at Week 423.0 ± 2.8
SecondaryChange From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4

Change from baseline in IOP for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eey. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period. A negative number change from baseline indicates an improvement.

Time frame:
Baseline, Week 4
Reported as:
Mean · Millimeters of mercury (mmHg)
Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
Millimeters of mercury (mmHg)Brimonidine 0.1%
Diurnal IOP Sitting at Baseline19.2 ± 2.7
Diurnal IOP Supine at Baseline23.1 ± 2.1
Nocturnal IOP Supine at Baseline22.7 ± 2.6
Diurnal IOP Sitting Change from Baseline at Week 4-2.4 ± 1.4
Diurnal IOP Supine Change from Baseline at Week 4-1.9 ± 1.3
Nocturnal IOP Supine Change from Baseline at Wk 40.3 ± 1.9
SecondaryOcular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4

Ocular perfusion pressure (OPP) calculated for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.

Time frame:
Week 4
Reported as:
Mean · Millimeters of mercury (mmHg)
Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4
Millimeters of mercury (mmHg)Brimonidine 0.1%
Diurnal OPP Sitting at Week 446.8 ± 7.6
Diurnal OPP Supine at Week 453.8 ± 9.8
Nocturnal OPP Supine at Week 449.2 ± 11.2
SecondaryChange in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4

Change in ocular perfusion pressure (OPP) calculated over a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at Week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.

Time frame:
Week 4
Reported as:
Mean · Millimeters of mercury (mmHg)
Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4
Millimeters of mercury (mmHg)Brimonidine 0.1%
Diurnal Change in OPP Sitting at Week 41.1 ± 5.6
Diurnal Change in OPP Supine at Week 40.3 ± 4.9
Nocturnal Change in OPP Supine at Week 4-3.0 ± 6.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brimonidine 0.1%—0/15 (0%)0/15 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Brimonidine 0.1%
Mean58.3 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Brimonidine 0.1%
Female10
Male5
08

Study locations

1 site
  • San Diego, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2007
First posted
Apr 9, 2007
Start
Dec 2006
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Nov 24, 2011
Last update
Nov 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00457795
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 9, 2007
Start date
Dec 2006
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Nov 24, 2011
Last update
Nov 24, 2011

Study contacts

Medical Affairs
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion